Company Overview
About FogPharma
FogPharma is a clinical-stage biopharmaceutical company founded in 2015 by Gregory Verdine and headquartered in Cambridge, Massachusetts, developing a novel class of cancer therapeutics based on cell-penetrating mini-proteins (CPMPs). Traditional cancer drugs fall into two broad categories: small molecules that can penetrate cells but struggle to bind complex protein surfaces, and antibodies that bind complex surfaces with high specificity but cannot enter cells. FogPharma's CPMPs are designed to do both — penetrate cell membranes and engage large, complex intracellular protein targets that cause cancer but have historically been considered undruggable.
Business Model & Competitive Advantage
FogPharma has raised $174 million in total funding, including a $100 million Series C in 2023 led by OrbiMed Advisors, with participation from existing investors including Third Rock Ventures, AbbVie Ventures, and GV (formerly Google Ventures). The company's lead program, FOG-001, targets the Wnt/beta-catenin signaling pathway — a driver of cancer proliferation in colorectal, liver, endometrial, and other cancers. Beta-catenin is one of the most frequently mutated oncoproteins in cancer but has not been successfully targeted by approved therapies due to the intracellular location and large surface area of its critical protein interactions.
Competitive Landscape 2025–2026
FogPharma is also pursuing programs targeting FOXM1, a transcription factor implicated in cancer cell survival and drug resistance. The company's scientific co-founder, Gregory Verdine, pioneered the hydrocarbon stapling technology that enables CPMPs to maintain their helical structure and cell-penetrating properties. FogPharma's approach represents a potential new therapeutic modality for cancer types that lack effective targeted therapies, particularly those driven by transcription factors and other historically intractable intracellular targets.
Key Differentiators
Emerging Innovator
FogPharma is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Circle Pharma
Circle Pharma is a clinical-stage biopharmaceutical company founded in 2016 by Matthew Jacobson, Siegfried Bhagwati, and Grace Aldrovandi, headquartered in San Francisco, California. The company is de
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Compare FogPharma with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from FogPharma? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim FogPharma Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention FogPharma vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →